Understanding Hemophilia A and B Drug Dosage Administration Patterns
NCT ID: NCT03248141
Last Updated: 2019-05-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
11 participants
OBSERVATIONAL
2017-09-01
2018-03-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A prospective observational, cross-sectional epidemiological study in U.S. site-based clinical practice settings.
30 sites will enroll approximately 300 patients
Participating patients - or their caregiver in the case of patients under the age of 18 - will be consented to participate.
Physicians complete a retrospective chart review on each enrolled patient.
Patients will complete a one-time study questionnaire.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PF-06741086 Multiple Dose Study in Severe Hemophilia
NCT02974855
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
NCT05568719
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors
NCT06312475
Study Evaluating Inhibitor Specificity in Hemophilia A
NCT00151385
Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry
NCT03603275
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hemophilia B
real world administration patterns and resource utilization implications
Hemophilia B standard half-life
Benefix
Hemophilia B extended half-life
Alprolix
Hemophilia A
real world administration patterns and resource utilization implications
Hemophilia A standard half-life
Xyntha and other standard half-life agents
Hemophilia A extended half-life
Eloctate and Adynovate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hemophilia B standard half-life
Benefix
Hemophilia B extended half-life
Alprolix
Hemophilia A standard half-life
Xyntha and other standard half-life agents
Hemophilia A extended half-life
Eloctate and Adynovate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* Mild Haemophilia A or B
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Florida College of Medicine
Gainesville, Florida, United States
Alliance for Childhood Diseases, dba Hemophilia Treatment Center of Nevada
Las Vegas, Nevada, United States
Cook Children's Medical Center
Fort Worth, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HEMOBAFS
Identifier Type: OTHER
Identifier Source: secondary_id
B1821056
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.